These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26463526)

  • 1. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL; Bethel J; Kapogiannis BG; Li T; Woods SP; Patton ED; Ren W; Thornton SE; Major-Wilson HO; Puga AM; Sleasman JW; Rudy BJ; Wilson CM; Garvie PA;
    J Neurovirol; 2016 Apr; 22(2):218-30. PubMed ID: 26463526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of antiretroviral therapy after the critical neuronal developmental period of the second postnatal year affects white matter microstructure in adolescents living with HIV.
    Hoare J; Heany SJ; Fouche JP; Phillips N; Joska JA; Myer L; Zar HJ; Stein DJ
    J Neurovirol; 2019 Apr; 25(2):254-262. PubMed ID: 30617850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtype associations with HIV-associated neurocognitive disorder in China.
    Day TR; Smith DM; Heaton RK; Franklin D; Tilghman MW; Letendre S; Jin H; Wu Z; Shi C; Yu X; Pérez-Santiago J
    J Neurovirol; 2016 Apr; 22(2):246-50. PubMed ID: 26306690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of Depressive Symptoms, Neurocognitive Function, and Viral Suppression With Antiretroviral Therapy Among Youth With HIV Over 36 months.
    Kohn JN; Loop MS; Kim-Chang JJ; Garvie PA; Sleasman JW; Fischer B; Rendina HJ; Woods SP; Nichols SL; Hong S
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):851-859. PubMed ID: 33587499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV.
    Harrison JD; Dochney JA; Blazekovic S; Leone F; Metzger D; Frank I; Gross R; Hole A; Mounzer K; Siegel S; Schnoll RA; Ashare RL
    J Neurovirol; 2017 Aug; 23(4):550-557. PubMed ID: 28429289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
    Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
    J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis.
    Gezie LD
    BMC Res Notes; 2016 Jul; 9():377. PubMed ID: 27475982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV.
    Kim-Chang JJ; Donovan K; Loop MS; Hong S; Fischer B; Venturi G; Garvie PA; Kohn J; Rendina HJ; Woods SP; Goodenow MM; Nichols SL; Sleasman JW;
    AIDS; 2019 Dec; 33(15):2363-2374. PubMed ID: 31764101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.
    Nichols SL; Bethel J; Garvie PA; Patton DE; Thornton S; Kapogiannis BG; Ren W; Major-Wilson H; Puga A; Woods SP
    J Adolesc Health; 2013 Dec; 53(6):763-71. PubMed ID: 23972941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.
    De La Mata NL; Ly PS; Ng OT; Nguyen KV; Merati TP; Pham TT; Lee MP; Choi JY; Sohn AH; Law MG; Kumarasamy N
    Int J STD AIDS; 2017 Nov; 28(13):1282-1291. PubMed ID: 28632481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of Steatosis to Neurocognitive Function in People Living with HIV.
    Marić D; Brkić S; Ignjatović VB; Nikolaševic Ž; Ilić D; Vujanović M; Drvendžija Z; Galić BS
    Curr HIV Res; 2020; 18(3):172-180. PubMed ID: 32106801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
    Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
    AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
    Sacktor N
    J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.